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ABSTRACT
Objective: A mixed-methods study exploring the UK
general public’s views towards consent for the use of
biosamples for biomedical research.
Setting: Cross-sectional population-based focus
groups followed by an online survey.
Participants: 12 focus groups (81 participants)
selectively sampled to reflect a range of demographic
groups; 1110 survey responders recruited through a
stratified sampling method with quotas set on sex, age,
geographical location, socioeconomic group and
ethnicity.
Main outcome measures: (1) Views on the
importance of consent when donating residual
biosamples for medical research; (2) preferences for
opt-in or opt-out consent approaches and (3)
preferences for different consent models.
Results: Participants believed obtaining consent for
use of residual biosamples was important as it was
‘morally correct’ to ask, and enabled people to make an
active choice and retain control over their biosamples.
Survey responders preferred opt-in consent (55%); the
strongest predictor was being from a low
socioeconomic group (OR 2.22, 95% CI 1.41 to 3.57,
p=0.001) and having a religious affiliation (OR 1.36,
95% CI 1.01 to 1.81, p=0.04). Focus group participants
had a slight preference for opt-out consent because by
using this approach more biosamples would be
available and facilitate research. Concerning preferred
models of consent for research use of biosamples,
survey responders preferred specific consent with
recontact for each study for which their biosamples are
eligible. Focus group participants preferred generic
consent as it provided ‘flexibility for researchers’ and
reduced the likelihood that biosamples would be
wasted. The strongest predictor for preferring specific
consent was preferring opt-in consent (OR 4.58, 95%
CI 3.30 to 6.35, p=0.015) followed by non-‘White’
ethnicity (OR 2.94, 95% CI 1.23 to 7.14, p<0.001).
Conclusions: There is a preference among the UK
public for ongoing choice and control over donated
biosamples; however, increased knowledge and
opportunity for discussion is associated with
acceptance of less restrictive consent models for some
people.
ARTICLE SUMMARY
Article focus
▪ To explore views of the UK public on the import-
ance of consent being sought for the use of
residual biosamples for medical research.
▪ The publics’ preferences for opt-in or opt-out
approaches to consent.
▪ The publics’ preferences for generic, tiered or
specific consent.
Key messages
▪ Obtaining consent for the use of residual bio-
samples for biomedical research was perceived
as important by members of the general public.
▪ Survey participants exhibited a desire to retain
active choice and control when donating biosam-
ples and over the uses to which their biosamples
might be put, preferring an opt-in system and
specific consent; however, these results differ
from those reported during focus group discus-
sions, where preference was for less restrictive
consent models (an opt-out system and generic
consent) that are likely to increase availability of
biosamples.
▪ These differences might be accounted for by the
fact that focus group participants were given
more background information about the use of
residual biosamples in research and had time to
consider the benefits and disadvantages of the
different approaches.
Strengths and limitations of this study
▪ This study contributes further to our understand-
ing of the UK public’s views and preferences
towards consent for the use of biosamples in
medical research. Our study supports the
premise that increased knowledge and opportun-
ity for discussion is associated with acceptance
of less restrictive consent models.
▪ Owing to the hypothetical nature of the study,
the findings may not necessarily correlate with
actual behaviour.
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INTRODUCTION
Human biological samples (biosamples), including
organs, tissues, bioﬂuids such as blood, and their deriva-
tives, are increasingly important resources for biomed-
ical research.1 2 For example, they can help us to
understand how we diagnose, categorise and treat a
whole variety of medical conditions including cancer1
and are particularly important when studying rare dis-
eases or conditions where biosamples are hard to
obtain. Biosamples are donated by either healthy volun-
teers or patients, either through speciﬁc research studies
or as residual tissues or bioﬂuids surplus to diagnostic
requirements, or postmortem. Biosamples can be used
fresh or can be ﬁrst stored in a biobank, a collection of
biosamples often linked with the donors’ clinical and
demographic information, as biosample attributes. Here,
the quality of the data linked to the biosample is as
important as the quality of the biosamples themselves,
providing essential context within which to design ana-
lyses and interpret results or carry our further experi-
mental studies. Clinical data may also be enriched with
lifestyle and environmental information.3
It is widely accepted that donor consent should be
sought and obtained before biosamples can be used in
research.4 5 Consent in research ethics relates to ensur-
ing respect for the autonomy and dignity of the donors
(research participants) and protecting them from
abuse5 and in fact, in England, Wales and Northern
Ireland, the Human Tissue Act establishes donor
consent as the baseline principle for the retention and
use of organs and tissue for purposes beyond diagnosis
and treatment, although further statutory consent
exemptions do exist in certain circumstances, notably
use of anonymised tissue from the living for research
ethics committee (REC) approved research projects.6
The value of biobanks, in supporting broad, long-term
research purposes, means that the model of the consent
process needs to be considered in order to ensure that it
is valid and appropriate. A number of different consent
frameworks which address consent scope and process
have been proposed as a result.5 However, there is con-
tinued debate as to which is the most appropriate in
various situations.4 7 8
Both the Human Tissue Authority9 and National
Research Ethics Service10 recommend generic consent
(table 1), a view that has also been endorsed by the UK
research funders11 and the Nufﬁeld Council on
Bioethics.12 One commonly cited criticism of generic
consent is that it is not sufﬁciently ‘informed’ as future
research uses are not known at the time of donation.13
Empirical research examining public and patient prefer-
ences has highlighted that there is no clear consensus
on the issue, with speciﬁc consent being identiﬁed as
the most favoured form of consent in some studies,14 15
and generic consent in others.16–18
The 2011 Nufﬁeld Council report on donation of
human material for medicine and research also recom-
mends that research funders should work to increase
Table 1 Approaches to consent of biosamples
Initial consent methods
Opt-in consent The storage and use of biosamples for research on the basis that the donor has actively
agreed to do so
Opt-out consent The storage and use of samples for research on the basis that the donor has not objected,
after previously being given the opportunity to do so
Opt-in consent methods
Consent once for life Consent is provided once for life for use of any residual samples for research with the option
of withdrawing permission at a later stage if the donor wishes to do so
Consent at certain points Consent is provided at certain points for use of residual biosamples for research, eg, every
10 years or at the beginning of a particular episode of care
Consent every time Consent is requested every time residual biosamples may become available for use in
research
Consent for research use of biosamples
Generic consent Consent to the use of donated samples for a range of unknown uses, on the basis of
general information about those possible uses and about the governance arrangements in
place. Also referred to as ‘broad’ or ‘blanket’ consent
Tiered consent A more restricted form of consent for use of samples, where the donor is invited to agree to
the use of their samples in unknown projects, but given the option of specifying particular
categories of research that they wish to exclude, eg, embryonic research. Also referred to as
‘categorical’ consent
Specific consent—once
only
Consent to the use of donated samples for a specified study only, on the basis of information
provided about that study. Any residual sample will be discarded at the end of that study
Specific consent—for every
new study
Consent to the use of donated samples for a specified study, on the basis of information
provided about that study. However, participants are recontacted and asked to consider
participating in every new study for which their biosamples are eligible
Consent terms were selected based on common usage within the UK biobanking system (eg, generic consent is the term used by the Human
Tissue Authority, National Research Ethics Service and National Cancer Research Institute) and definitions chosen in consultation with a
team of representatives from universities, hospital biobank staff, pathologists and industry.
2 Lewis C, Clotworthy M, Hilton S, et al. BMJ Open 2013;3:e003022. doi:10.1136/bmjopen-2013-003022
Open Access
 group.bmj.com on February 13, 2014 - Published by bmjopen.bmj.comDownloaded from 
public awareness of the key role of donated tissue in sci-
entiﬁc and clinical research.12 Public trust and conﬁ-
dence in the consent process is of paramount
importance to maintain and increase public support for
donation and use of biosamples for biomedical research
in the UK. For this reason, it is important to understand
and inform public opinion to ensure that consent models
are aligned to public expectations and preferences.
While numerous international studies have been con-
ducted which focus on consent preferences, research
conducted in the UK has tended to focus on large-scale
population biobanks, such as the UK Biobank19 or
Generation Scotland,20 which require ongoing contact
with donors, or on the views of patients on the donation
of residual biosamples.21 The current study was con-
ducted to broaden our understanding of the UK public’s
views on biosample donation for biomedical research.
Moreover, the ﬁndings are intended to inform a biobank-
ing policy for Strategic Tissue Repository Alliance
Through Uniﬁed Methods, a Technology Strategy Boardi
and pharmaceutical industry-funded project seeking to
address the problem of insufﬁcient numbers of biosam-
ples and associated clinical data of adequate quality to
fully support biomedical research in the UK.
The speciﬁc aims of this study were to (1) identify par-
ticipants’ views on the importance of consent when
donating residual biosamples for medical research;
(2) explore preferences for opt-in or opt-out approaches
to consent and (3) explore preferences for different
consent models (table 1). Public willingness to donate
biosamples, views on donation of different biosample
types and conditions of their use (by which organisa-
tions and for which types of research) are reported in
the sister paper related to this study.22
METHODS
This was a mixed methods study comprising qualitative
focus groups and a quantitative on-line survey. Ethical
approval for the study was granted by the University of
Manchester Research Ethics Committee in April 2012.
Focus groups
Twelve focus groups (including one pilot group) were
conducted between May and July 2012 in six different
geographic locations across the UK. Participants were
recruited face-to-face in the street by a market research
company, The Focus Group. Participants were purpos-
ively sampled; each group chosen to reﬂect a particular
demographic (age, socioeconomic group (SEG), ethni-
city) in order to gather a wide spectrum of views and
enable comparisons across groups. Two ‘patient’ groups
were also included, comprising people who had had an
operation in the past 2 years requiring an overnight
hospital stay, and people who currently have, or have
had, either a serious or chronic illness or disability. The
latter group comprised people diagnosed with diabetes,
cancer, heart disease, asthma and the genetic condi-
tions, like Marfan syndrome. A further group consisted
of generally healthy volunteers who had donated a bio-
sample speciﬁcally for research purposes.
Before agreeing to take part, potential participants
were given a participant information sheet telling them
about the study (see online supplementary appendix I).
Those who were interested were screened through a
questionnaire containing demographic questions to
assess their suitability for a particular focus group. These
were held in ‘neutral’ locations such as hotel conference
rooms or church halls and facilitated by an experienced
facilitator (CL). Before each group discussion, partici-
pants were sent a short information leaﬂet about the use
of biosamples in biomedical research to provide some
background context for the discussion and to prompt
them to think about the key issues (see online supple-
mentary appendix II). This information was written by a
core team of authors drawn from across academia and
industry, including patient representation. It was
reviewed by three members of the patient organisation
Genetic Alliance UK as well as the science communica-
tion charity Sense about Science to ensure readability
and non-bias. Before focus group discussions began, par-
ticipants were asked to sign a consent form. Each partici-
pant received £50 for taking part to cover time and
travel costs. Focus groups lasted 90 min and digital
audio recordings were taken.
A detailed discussion guide was developed to explore
participant views and preferences towards consent scope
and process (see online supplementary appendix III).
The main focus related to the use of biosamples surplus
to diagnostic requirements following surgery or a medical
procedure. Questions were informed by other empirical
studies of consent in biobanking,16 23 developed by the
authors and addressed the topics described above. To
enhance understanding around the different consent
models, participants were given a sheet presenting three
different scenarios, each of which elaborated on one of
the three consent models chosen for discussion (see
online supplementary appendix III, p.4). For each topic,
discussions began by asking the group to consider the
beneﬁts and disadvantages of each particular approach.
Once no new themes were emerging, each participant
was asked to complete an accompanying anonymous
questionnaire which asked them to select their preferred
consent model. The discussion guide, scenario sheet and
questionnaire were piloted at the ﬁrst focus group which
resulted in some minor amendments to wording.
Recordings were fully transcribed and transcriptions
checked. The software package Nvivo V.9 (QSR
International, Pty Ltd) was used to help organise the
data for analysis. This comprised grouping responses to
questions into broad thematic categories which were
then reﬁned through subcodes. Coding of all 12
iUnder the Stratiﬁed Medicines Programme: Business Models Value
Systems.
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transcripts was conducted by CL. The ﬁrst six transcripts
to be coded were also independently coded by a second
researcher (SR). Codes were then compared to assess
consistency of coding and ensure inter-rater reliability.
Any discrepancies were discussed until consensus was
reached. The remainder of the transcripts were then
coded according to the agreed coding framework.
Survey
Once data analysis had been conducted on the focus
group transcripts, the ﬁndings were used to inform
development of a quantitative survey which was used to
canvas public opinion on the issues of interest across a
representative sample of the UK population (see online
supplementary appendix IV). The survey was carried out
by the market research company Research Now using
their online panel community of the UK residents. A
stratiﬁed sampling method was used: quotas were set on
sex, age, geographical location, SEG and ethnicity, in
line with data provided by the Ofﬁce of National
Statistics (ONS) to ensure the sample was as representa-
tive of the UK population as possible. Within each cat-
egory, a random sample was selected from the Research
Now database containing 451 185 active respondents. We
aimed to recruit 1000 responders in total. The sample
size required depends on the number of predictors, the
expected effect size and the level of power. According to
Miles and Shevlin,24 if we are expecting a small effect
size, a sample size of 600 is considered adequate to
achieve a high level of power of 0.8 (a benchmark sug-
gested by Cohen25) for four predictors. As highlighted
in table 2 we can formulate at least four hypothesis, for
example, people from a higher SEG are more likely to
donate biosamples than those from a lower SEG. With a
sample size of 1000, this study would provide highly reli-
able results. In order to reduce any on-line bias in our
sample, 100 face-to-face interviews with non-internet
users were conducted. An additional ‘boost’ sample of
100 people (not included in the main sample analysis)
was also conducted with people from three minority eth-
nic groups (‘Black’, ‘Chinese’, ‘S Asian’) so that we
could conduct subgroup analysis between the groups.
The survey questions were developed by the authors
and piloted with 60 members of Research Now’s online
panel community who were from low SEG’s. Members of
the pilot group were then invited to take part in a subse-
quent telephone interview asking about the survey.
Interviews were conducted with 25 pilot survey respon-
ders. Questions focused on question clarity, survey
length and whether responders felt the survey to be
neutral. Some minor amendments to wording were
made in light of the responses. The main survey was
then conducted in September 2012. Surveys recorded
online took, on average, 17 min to complete and each
responder received a small payment (around £2) from
Research Now.
Survey data were organised and analysed using SPSS stat-
istical software V.20 (SPSS Inc; 2011; Chicago, Illinois,
USA). Initial univariate descriptive statistics were obtained
for the entire study. Pearson χ² test was used to examine
demographic factors associated with willingness to donate
and preference for different consent models. Those asso-
ciations that were found to be signiﬁcant (p≤0.05) were
then entered into a multiple logistic regression to explore
the predictivity of these variables. Before running the
model, we tested for multicollinearity among the inde-
pendent variables. No multicollinearity issues were found.
RESULTS
Study populations
Participant characteristics are detailed in table 2.
Focus groups
One hundred and eighty-two members of the public who
were approached were eligible to participate (ie, they ﬁtted
the criteria for a particular focus group) and 81 people
agreed to participate (45% participation rate; 48 women,
33 men). There were seven participants in each focus
group apart from the 18 –25 age group and high SEG
group (eight participants in each); serious/chronic illness
group and healthy volunteers group (six participants in
each) and the pilot group (ﬁve participants).
Survey
In total, 4607 people were invited to take part in the
survey; 2014 did not respond, 860 began completing the
survey but did not ﬁnish, 102 did not qualify to continue
(eg, they were under 18 years old), 521 qualiﬁed for the
survey but the quota was full and 1110 completed the
questionnaire (28% response rate excluding those who
did not qualify and where the quota was full). This
response rate is comparable with similar studies on this
topic.16 Our participant quotas closely, though not
exactly, matched our targets based on the UK popula-
tion data as provided by the ONS. For this reason we
carried out both weighted and unweighted analyses.
There was no difference in the conclusions we reached
by either method. In this paper we present the
unweighted results (weighted results can be found at
online supplementary appendix V).
Importance of asking for consent
The majority of survey participants believed that obtain-
ing consent for the use of residual biosamples was either
extremely important (55%) or important (25%). Only
4% selected ‘not at all important’. Focus group partici-
pants also saw the consent process as important and
cited reasons including: that it was ‘polite’, ‘respectful’
and ‘morally correct’ to ask permission; that it enabled
people to feel they had made a contribution and an
active choice; that it provided control, in particular for
those people that might not want their biosamples to be
used, for example, for religious reasons; that taking
without asking was akin to theft; and that it was
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Table 2 Participant characteristics
Characteristic
Focus group
N=81
Survey
N=1110
Gender
Male 33; 41% 504; 45%
Female 48; 59% 606; 55%
Age
18–24 13; 16% 135; 12%
25–34 18; 22% 184; 17%
35–44 19; 23% 198; 18%
45–54 10; 12% 184; 17%
55–64 16; 20% 176; 16%
65+ 5; 6% 233; 21%
Socioeconomic group
A 9; 11% 41; 4%
B 22; 27% 215; 19%
C1 24; 30% 311; 28%
C2 14; 17% 233; 21%
D 6; 7% 145; 13%
E 6; 7% 165; 15%
Region
East of England 7; 7% 92; 8%
East Midlands – 57; 5%
London 18; 22% 213; 19%
North East – 40; 4%
North West – 121; 11%
Northern Ireland – 30; 3%
Scotland 14; 17% 76; 7%
South East 14; 17% 165; 15%
South West – 81; 7%
Wales – 51; 5%
West Midlands 14; 17% 94; 8%
Yorkshire/Humberlands 14; 17% 90; 8%
Ethnicity
White or White British 54; 67% 1057; 95%
Mixed race 1; 1% 7; 1%
Asian or Asian British 10; 12% 18; 2%
Black or Black British 9; 11% 19; 2%
Chinese or Chinese British 7; 9% 2; 0%
Other ethnic group 0; 0% 4; 0%
Prefer not to say 0; 0% 3; 0%
Religion
Christianity 677; 61%
Islam 13; 1%
Hinduism 6; 1%
Sikhism 0; 0%
Judaism 6; 1%
Buddhism 11; 1%
Other religion 15; 1%
No religion 370; 33%
Prefer not to say 12; 1%
Religiosity
Not at all religious 234; 32%
Moderately religious 422; 58%
Very religious 64; 9%
Prefer not to say 8; 1%
Education
No formal qualification 15; 19% 70; 6%
GCSE, O level, Scottish Standard Grade or equivalent 19; 23% 264; 24%
GCE, A-level, Scottish Higher or similar 17; 21% 214; 19%
Continued
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important in order to maintain trust between patients
and doctors.
It then doesn’t allow them to take liberties or advantage
of the fact that you’re out cold having an operation and
someone says ‘Oh we need a bit of that’. Male, patient—
had operation in past 2 years
A small minority did not feel that consent was import-
ant, the main reasons being that they did not want the
tissue back, that once it was removed it no longer
‘belonged to them’, and that the tissue would just go to
waste otherwise.
Survey participants were asked what would be their
preferred method of consenting to donate leftover bio-
samples for research use. The majority (65%) wanted to
do so face-to-face with a health professional; 15%
wanted to complete a form and return it by post. This
issue was not speciﬁcally addressed with focus group par-
ticipants due to time constraints.
Preference for ‘opt-in’ or ‘opt-out’ consent
Participants were asked whether they preferred an opt-in
or opt-out model of consent for donating residual bio-
samples. The results of the survey showed that opt-in
consent was preferred by over half of the participants
(55%), 28% preferred opt-out, 14% had no preference
and 4% selected ‘don’t know’. Participants who were
signiﬁcantly more likely to prefer opt-in consent were:
from a low SEG (E) (79.8% vs 64.1%, χ²=11.13(1),
p=0.001); over 65 years (75.1% vs 64%, χ²=7.68(1),
p=0.006); had a religious afﬁliation (68.8% vs 61.2%,
χ²=4.84(1), p=0.028); and had an education level of
GCSE or lower (71.1% vs 63.9%, χ²=3.89(1), p=0.048).
The strongest signiﬁcant predictor for preferring opt-in
consent was being from a low SEG (E) (OR=2.22, 95%
CI 1.41 to 3.57, p=0.001) followed by having a religious
afﬁliation (OR=1.36, 95% CI 1.01 to 1.81, p=0.04; table
3).
Focus group participants preferred opt-out consent
(n=46; 57%) over opt-in consent (n=29; 36%), with six
participants (7%) unsure, after in-depth discussion
around the beneﬁts and disadvantages of each
approach. The main beneﬁt of opt-out consent cited by
participants was that more biosamples would be available
and consequently spur research. Other reasons
included: that it would be less costly administratively;
that it maximised the value of left over biosamples; that
patients would not have to consider it every time they
were having an operation or blood test; that those that
did not want to donate still had the opportunity to
opt-out and that it would ‘normalise’ donating leftover
biosamples which would be a positive step.
It would be an incentive for society if everyone knew that
this is what happens routinely, but you can choose not to
Table 2 Continued
Characteristic
Focus group
N=81
Survey
N=1110
Vocational (BTEC/NVQ/diploma) – 230; 21%
Degree level or above 30; 37% 317; 29%
Prefer not to say – 15; 1%
Self-reported knowledge of medical research process
No knowledge 463; 42%
Some knowledge 603; 54%
Good knowledge 44; 4%
Have you been affected by a disability or illness?
Yes 399; 36%
No 711; 64%
Has a close family member been affected by a disability or illness?
Yes 767; 69%
No 343; 31%
Have you had blood or tissue removed during a medical procedure?
Yes 446; 40%
No 553; 50%
Don’t know 111; 10%
Have you ever been asked to donate blood or tissue for medical research?
Yes 182; 16%
No 904; 81%
Don’t know 24; 2%
If so, did you agree to donate?
Yes 155; 85%
No 23; 13%
Don’t know 4; 2%
Percentages may not add up to 100 due to rounding.
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be involved. It would be more like ‘that’s normal’. Male,
aged 18–24 group
Those that preferred the opt-in approach cited the fol-
lowing reasons as to why: an active choice whereby parti-
cipants had to act on a decision to take part was
preferable to a passive choice whereby consent was
assumed; it enabled people to have more control over
their biosamples; it was truly ‘informed consent’ in the
context of donating surplus samples for research (rather
than as part of a clinical trial; clinical trials were outside
the scope of the study) and hence more ethically accept-
able; it enabled people to feel that they were making a
positive contribution and would prevent the problem of
vulnerable groups not being aware they were automatic-
ally ‘opted-in’.
There are going to be members of the public who are
not going to always be able to consider rationally them-
selves what it actually means. Female, healthy volunteer
While the majority of focus group participants overall
preferred opt-out consent, the results were different for
the three minority ethnic groups (‘Black’, ‘S. Asian’ and
‘Chinese’), where opt-in consent was favoured by the
majority.
Consent once for life or consent every time
The most prevalent system in current use for donating
new biosamples that are surplus to clinical requirements
in the UK is the opt-in approach, with potential donors
being asked for consent every time a procedure is per-
formed that may result in a biosample becoming avail-
able for research. (The law allows for the use of
diagnostic archives for research without consent as long
as certain criteria are met.) Participants were therefore
asked to consider variations on this model and state
whether they preferred: (1) consent once for life, cover-
ing all subsequent biosamples, until or unless the donor
decides to withdraw consent; (2) consent every time
samples surplus to diagnostic requirements may become
available or (3) consent at certain points in life. Consent
every time (43%) was preferred by the majority of survey
participants, followed by consent at certain points (27%)
and consent once for life, for example, at age 18 (21%).
Seven per cent had no preference and 2% did not
know. Groups who were signiﬁcantly more likely to
prefer consent every time compared with consent once
for life were: under 55 years (70.3% vs 60.9%; χ²=5.88
(1), p=0.015); had no knowledge of the research process
(72.3% vs 63.4%; χ²=5.77(1), p=0.016) or were either
not at all or moderately religious (70.2% vs 51.3%;
χ²=5.1(1), p=0.024). When entered into the regression
analysis, the strongest signiﬁcant predictor for preferring
consent every time was being not at all or moderately
religious (OR=2.04; 95% CI 1.05 to 4.00, p=0.036) fol-
lowed by being under 55 years (OR=1.60; 95% CI 1.07
to 2.41, p=0.023; table 3).
Unlike survey responders, focus group participants
favoured consent once for life (n=35; 43%) followed by
consent every time samples surplus to diagnostic require-
ments may become available (n=27; 33%) and consent
at certain points (n=16; 20%) with three choosing do
not know (4%). Like opt-out consent, consent once for
life was seen to be better as it was ‘quicker’ and ‘easier’
administratively and prevented researchers from ‘losing
out’. Consent provided most control for participants as
you would ‘know the speciﬁc purpose of it’, particularly
if the sample was considered to be sensitive, for
example, eggs; allowed ‘no room for error’; and enabled
people to change their mind easily.
You may feel differently [depending on] what tissue is
being donated and for what purpose the research is
being carried out. Female, aged 18–24 group
Some participants had concerns about how consent
preferences (eg, what types of research they were willing
Table 3 Multiple logistic regression of participant preferences for consent models
Participant characteristic Coefficient 95% CI OR p Value
Preference for opt-in consent
Socioeconomic group 0.806 1.41 to 3.57 2.22 0.001
Religion 0.304 1.01 to 1.81 1.36 0.04
Preference for consent every time
Religion 0.72 1.05 to 4.00 2.04 0.036
Age 0.47 1.07 to 2.41 1.60 0.023
Preference for specific consent
Opt-in 1.52 3.30 to 6.35 4.58 <0.001
Ethnicity 1.08 1.23 to 7.14 2.94 0.015
Preference for generic consent
Opt-out 1.52 3.13 to 6.67 4.55 <0.001
Religion 0.04 1.08 to 2.72 1.56 0.021
Knowledge of medical research process 0.44 1.06 to 2.28 1.56 0.024
Demographic items were excluded from this table if none was statistically significant. All variables were entered into the models as categorical
variables.
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to donate a biosample for), would follow them across
the healthcare system if a ‘consent once for life’ model
was adopted. Consent at certain points was seen by some
as a good middle ground as patients would still have
some control, but would not have to go through the
consent process every time they had a medical proced-
ure. Examples of consent at certain points included
every ‘5 or 10 years’, or at the beginning of particular
episodes of care such as pregnancy or cancer treatment.
Models of consent for research use of biosamples
Survey participants were presented with four consent
models (table 1), and asked whether they would con-
sider consenting residual biosamples to each of them,
providing the research had been approved by a REC
(described as a committee usually made up of doctors,
scientist, patients and the general public which ensure
any research allowed to be carried out is for the beneﬁt
of patients). Eighty per cent would agree to speciﬁc
consent—once only; 77% would consent to speciﬁc
consent—for every new study; 71% would agree to
tiered consent and 67% of participants would agree to
generic consent. When asked which model they pre-
ferred, speciﬁc consent—for every new study, was the
ﬁrst choice among those who had a preference (30% of
participants overall), followed by generic consent and
speciﬁc consent—once only, jointly second (both 18%)
and lastly tiered consent (14%). Sixteen per cent had
no preference and 6% did not know.
After collapsing the two speciﬁc consent models
together (speciﬁc consent—for every new study and spe-
ciﬁc consent—once only), those participants who pre-
ferred speciﬁc consent were signiﬁcantly more likely to:
have a religious afﬁliation (63.9% vs 48.9%, χ²=16.88(1);
p<0.001); live in the North East or Scotland (60.9% vs
42.7%, χ²=10.23(1), p=0.001); be over 65 years (67.1% vs
57.1%, χ²=5.31(1), p=0.021) and be of a non-‘White’ eth-
nicity (68.9% vs 58%, χ²=4.17(1), p=0.041). Using the
boost sample we found that ‘Black’ participants were sig-
niﬁcantly more likely to prefer speciﬁc consent models
compared with ‘White’ participants (75.6% vs 58%,
χ²=4.31(1), p=0.038). Those people who preferred opt-in
consent were also more likely to prefer speciﬁc consent
models (71.1% vs 35.3%, χ²=91.72(1), p<0.001). The
strongest signiﬁcant predictor for preferring speciﬁc
consent was preferring opt-in consent (OR=4.58, 95%
CI 3.30 to 6.35, p<0.001) followed by being of
non-‘White’ ethnicity (OR=2.94, 95% CI 1.23 to 7.14,
p=0.015; table 3).
We also looked at who was most likely to prefer generic
consent, the least restrictive of the proposed consent
models. Those who preferred generic consent were sig-
niﬁcantly more likely to: have no religious afﬁliation
(51.1% vs 36.1%, χ²=15.97(1), p<0.001); have some or
good knowledge of the medical research process (26.1%
vs 18.3%, χ²=6.79(1), p=0.009); be male (26.8% vs 19.9%,
χ²=5.40(1), p=0.02) and be from a higher SEG group (A–
D) (24.3% vs 15.1%, χ²=4.66(1), p=0.031). They were also
signiﬁcantly more likely to prefer opt-out consent (64.7%
vs 28.9%, χ²=91.72(1), p<0.001). The strongest signiﬁcant
predictor for preferring generic consent was preferring
opt-out consent (OR=4.55, 95% CI 3.13 to 6.67, p<0.001)
followed by having no religious afﬁliation (OR=1.56, 95%
CI 1.08 to 2.72, p=0.021) and some or good knowledge of
the medical research process (OR=1.56, 95% CI 1.06 to
2.28, p=0.024; table 3).
Focus group preferences differed from those of survey
responders with generic and tiered consent being
equally popular (n=36; 44% and n=35; 43%, respect-
ively). Speciﬁc consent—once only, was least popular
(n=6; 7%) (this was the only speciﬁc consent model
given to participants). Four participants (5%) did not
know. Generic consent was valued as it provides most
‘ﬂexibility for researchers’; reduces the likelihood
residual biosamples will go to waste; is more straightfor-
ward to put in place; is ‘simpler to understand’ and
enables biosamples to be used for more than ‘one spe-
ciﬁc thing’.
It’s better not to restrict the possible use of the sample
because by restricting it you’re increasing the chance that
it’ll go to waste. You want the highest probability that
something good will come from it. Male, patient—
affected by a condition
It was also the consent model favoured by all partici-
pants who were affected by an illness or disability.
Tiered consent was valued because it provided more
control over donated biosamples than generic consent,
allowing people to opt-out of certain types of research,
and therefore provided ‘clarity and peace of mind’. All
but one participant in the ‘Black’ focus group and all par-
ticipants who had donated biosamples as healthy volun-
teers preferred tiered consent. While speciﬁc consent was
seen to provide the most control and enabled partici-
pants to have ‘some understanding of what it might be
used for’, concerns raised were that it ‘can’t be used for
anything else’, ‘could be wasted’ and would require a
time-consuming explanation from health professionals.
In both the survey and focus groups, the donation of
potentially sensitive biosamples produced a preference for
speciﬁc consent. In the survey, a quarter (25%) preferred
speciﬁc consent—for every new study, 22% preferred spe-
ciﬁc consent—once only, 12% preferred generic consent
and 9% preferred tiered consent. Nineteen per cent had
no preference and 13% did not know. When discussing
donation of eggs, one woman commented:
People could reproduce a child or whatever and it’s
about the personal-ness of what’s been taken from you.
So if it’s a bit of blood, yeah take it, I mean you just cut
yourself and blood is gone, but if it’s something that’s
quite personal you only have every now and again, that
needs to be guarded. Female, ‘Black’ ethnicity group
We asked survey participants whether they would like to
be kept up-to-date with research going on at a particular
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hospital or biobank to which they had donated a biosam-
ple. Eighty-ﬁve per cent said they would be interested;
the most popular methods to receive updates were via a
website (27%), email (27%) or letter (22%).
DISCUSSION
This study contributes further to our understanding of
the UK public’s views and preferences towards consent
for the use of biosamples in medical research. In
summary, we have found that: (1) the consenting
process was perceived as important in order to maintain
trust between patients and health professionals and
respect patient autonomy; (2) survey participants exhib-
ited a desire to retain active choice and control when
donating biosamples and over the uses to which their
biosamples might be put and (3) these results differ
from those reported during focus group discussions,
where preference was for less restrictive consent models
that are likely to increase availability of biosamples.
These differences might be accounted for by the fact
that focus group participants were given more back-
ground information about the use of residual biosam-
ples in research and had time to consider the beneﬁts
and disadvantages of the different approaches. These
interventions may have allayed any anxieties participants
had about relinquishing control of their biosamples and
seem to have encouraged participants to choose
approaches that maximised biosample access to
researchers, highlighting the importance and potential
impact of education on inﬂuencing public perception in
this area.
The preference for opt-in consent identiﬁed in the
survey is consistent with the results of other studies in
this area.3 15 16 One reason for this preference may be
that it matches the current system for organ donation
for transplant in the UK. It was also perceived as being
truly informed consent by some participants (although
it is worth noting that it is the information provided to
potential donors that guarantees consent is informed
rather than the consent mechanism). Nevertheless, the
sizeable number of survey responders who preferred
opt-out consent (27%) coupled with the preference for
opt-out among focus group participants (57%) does
suggest that there may be broader support than previ-
ously believed for this approach. This point is also sup-
ported by the ﬁnding that fewer than half of survey
participants wanted to be consented every time a sample
was taken and nearly 30% preferred consent at certain
points. Alternate, more streamlined approaches to con-
senting should therefore be considered and evaluated.
Interestingly, our results showed that preference for
opt-out consent was associated with being younger
(under 65 years), from a higher SEG and a higher edu-
cation level. These demographic groups may be more
trusting of medical institutions to use residual biosam-
ples appropriately, or perhaps feel empowered to be
able to opt-out if so desired, for example, online. Similar
ﬁndings have been reported in relation to organ dona-
tion; a study by Gimbel et al26 found an association
between cadaveric donation rate and percentage of the
population enrolled in third-tier education. Internet
access has also been found to correlate with increased
organ donation.27
Concerning consent models for research use of bio-
samples, the majority of people (69%) were willing to
donate biosamples via the least restrictive model,
generic consent. A study conducted in Sweden found a
similar percentage of the general public were happy to
agree to generic consent (67%), whereby surrogate deci-
sions were performed by a REC.28 Other national
studies have found the acceptability of generic consent
among the general public and in particular patients to
be higher, between 79% and 95%.4 29–32 Nevertheless,
our survey ﬁndings suggest that willingness to donate
increased where greater choice and control over
research participation is retained, although the differ-
ence between those who were willing to agree to generic
compared with speciﬁc was only 13%. Similarly, when
survey responders were asked about their preferred
approach, their preference was also for speciﬁc consent
for every new study that might be conducted using their
biosample. This may indicate a general interest in how
samples are being used. This notion is supported by the
high number of people who wanted ongoing contact
about the research leading from their donation.
Moreover, they may have not considered the practical-
ities of being asked to consent every time their sample is
used, and the high level of recontact they might receive
from research teams. Nevertheless, it is important to
take note of the fact that more tailored forms of consent
represent an attractive approach to many people. While
speciﬁc consent may be practical for individual research
projects, this restriction would make biobanking challen-
ging, as biobanks exist to facilitate access to samples for
a wide variety of approved research projects without the
need for additional consent. It may be that as more
sophisticated biosample tracking and management
systems are adopted, resources could become available
to support more interactive forms of consent, and more
biobanks could offer tiered consent, for example.
Further public dialogue and information about the use
of the samples may also provide the same assurances for
people that arise from speciﬁc consent, as highlighted
by the preference for less restrictive consent models
among focus group participants.
Evidence from other empirical studies looking at pre-
ferences for consent models is mixed. The UK studies
focusing on donations purely for research by ‘healthy
volunteers’ to biobanks (ie, not donating residual bio-
samples) have identiﬁed a preference for speciﬁc
consent,19 33 as did a study conducted in the USA that
also focused on healthy volunteers.15 In a pan-European
survey, the majority of the UK public also preferred spe-
ciﬁc consent for every new study, although the percent-
age that did was slightly lower than the overall European
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average (65% compared with 67%).34 It was, however,
higher than in Denmark and Finland, where the per-
centage of people who wanted to be recontacted for
every new study was lower at 51% and 54%, respectively.
These countries were also found to have very few con-
cerns about the collection of personal information by
biobanks and had high levels of trust in ethics commit-
tees. Other empirical work conducted in the USA,
Canada, Sweden and Spain has shown that public prefer-
ence is for generic consent.3 16 18 35 36 These ﬁndings
highlight the divergence of opinion on this issue, in par-
ticular in different contexts and with different informa-
tion provision, although the difﬁculty of comparing
across studies with different methodologies and back-
grounds must also be taken into account. Notably, where
participants had some or good knowledge of the
research process and where there was in-depth discus-
sion (ie, during focus groups), participants were more
likely to prefer generic consent, a ﬁnding that has also
been identiﬁed elsewhere in the literature37 and sup-
ports the need for information and education if increas-
ing the acceptability of generic consent is deemed
desirable. Focus group participants affected by an illness
or disability were also found to prefer generic consent,
and is likely to reﬂect the fact that they have greater
interests at stake.38 Preference for speciﬁc consent was
found to be associated with being over 65 years and
from a non-‘White’ ethnicity, ﬁndings which resonate
with other studies.3 39 40 Consent documentation and
written information targeted speciﬁcally at these particu-
lar groups may also help alleviate any speciﬁc concerns
these groups may have.
This research into current public attitudes regarding
biosample donation in the UK provides valuable guid-
ance for biobanking governance. While generic consent
is the model largely endorsed by regulators and funders
in the UK,9 11 the evidence from this study suggests that
there is a need to address the potential concerns that
some people may have about the minimal information
and lack of control provided through this model.
Education and opportunity for discussion may be one
way to allay concerns, as demonstrated through focus
groups. Keeping donors informed of current research
taking place at the hospital or research institutions to
which they donated also appears to be desirable and is
likely to be both motivating and promote public trust
and conﬁdence in the research process, a ﬁnding
reported elsewhere.41 The opportunity for face-to-face
discussion with an appropriately trained healthcare pro-
fessional at the time of donation may also allay any
potential concerns, and is indeed the approach usually
taken in the UK at present. This approach has been
found to yield high acceptance rates among patients of
well over 90%.42–44
Strengths and limitations
This was a mixed-methods study to explore public views
and preferences towards consent for biosample donation.
Integrating quantitative and qualitative approaches is
valuable in exploratory research as it can strengthen the
inferences made through triangulation and allow for a
more nuanced understanding of the topic.45 This study
presented participants with a series of hypothetical ques-
tions about their preferences and willingness to donate
residual biosamples for medical research. By presenting
questions as ‘real life’ scenarios, we hoped to make the
questions as realistic as possible. However, as with any
hypothetical scenario, the ﬁndings may not necessarily
correlate with actual behaviour.
The questions for both the focus groups and the
survey were piloted to ensure they were clear and under-
standable and were not biased towards any particular
viewpoint. Nevertheless, many of the issues covered were
complex, particularly around the meaning of the differ-
ent consent models which may have contributed to the
dropout rate. Focus groups participants were not pre-
sented with the option of ‘speciﬁc consent—for every
new study’ (they were only given ‘speciﬁc consent—once
only’). This may have been an attractive option for some
given that a concern raised was biosamples being wasted.
However, given that the key reasons participants’ valued
generic consent were because it provided most ﬂexibility
to researchers and was most straightforward to adminis-
ter, this seems unlikely. In addition, given time and
resource constraints we were unable to explore whether
‘stronger’ consent models would have been preferable
for organisations that donors trusted less. This is an area
that would be worth exploring further in future
research. Some participants did complete the survey pos-
sibly because of strong feelings about the issues raised
and this may have skewed the results; however, every
effort was made to ensure that the results were as repre-
sentative of the UK population as possible. The focus
groups and survey were conducted in English and so the
ﬁndings may not be representative of non-English speak-
ing members of the general public. Future research
might target these particular groups.
CONCLUSION
There is a general willingness among the UK population
to donate biosamples for medical research. Our research
suggests that there is a preference among the UK public
for more information on the uses and outcomes of
research, and ongoing choice and control over donated
biosamples. Our study also supports the premise that
increased knowledge and opportunity for discussion is
associated with acceptance of less restrictive consent
models.
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